Grace Therapeutics prices $10 million private placement at $2.10 per share
Grace Therapeutics sold 4,761,904 shares of common stock at $2.10 per share in a private placement to institutional and accredited investors, for approximately $10 million in gross proceeds before placement agent fees and expenses. The offering closed on August 6, 2026. The company expects the proceeds, with existing cash, to extend its cash runway to the end of calendar 2028, but the new shares add to the outstanding share count and the company has agreed to register them for resale.
Key points
- 4,761,904 shares sold at $2.10 per share, for approximately $10 million in gross proceeds
- Offering closed August 6, 2026; Craig-Hallum Capital Group LLC acted as placement agent
- Company expects cash runway to extend to the end of calendar 2028; proceeds will support manufacturing and regulatory work for GTx-104
- Company agreed to register the resale of the shares and generally may not issue more shares or file a registration statement for 90 days after closing, subject to exceptions
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.